Phase II study of pemetrexed plus gemcitabine in advanced pancreatic cancer

American Journal of Cancer

Volumn 4, Issue 3, 2005, Pages 185-191

  Kindler, Hedy L ^a   Dugan, William M ^b   Hochster, Howard ^c   Strickland, Donald K ^d   Jacobs, Andrew ^e   Hayden, Anna Marie ^f   Liepa, Astra M ^f   John, William J ^f  

^a UNIVERSITY OF CHICAGO   (United States)

^b Gynecologic Cancer Care   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d Memphis Cancer Center Inc   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIINFECTIVE AGENT; CYANOCOBALAMIN; DEXAMETHASONE; FLUOROURACIL; FOLIC ACID; GEMCITABINE; PEMETREXED;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG RESPONSE; ENZYME BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; RASH; SEPSIS; SURVIVAL; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 23744434331     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200504030-00005     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55: 10-30
2. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′2′ difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 10: 29-34
3. Burris HA, Moore M, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13
4. Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001; 60: 8-18
5. Kroep JR, Pinedo HM, van Groeningen CJ, et al. Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 1999; 10 Suppl. 4: S234-8
6. Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999; 26 (2 Suppl. 6): 42-7
7. Shih C, Chen VJ, Gossett LS, et al. LY231514 a pyrrolo [2,3-d] pyrimidine based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 1997; 57: 1116-23
8. Britten CD, Izbicka E, Hilsenbeck S, et al. Activity of the multitargeted antifolate LY231514 in the human tumor-cloning assay. Cancer Chemother Pharmacol 1999; 44 (2): 105-10
9. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514) administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999; 44: 372-80
10. Miller KD, Picus J, Blanke C, et al. Phase II study of the multitargeted antifolate LY231514 (Alimta, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000; 11: 101-3
11. Schultz R, Rothenberg M, Koury M, et al. Sequence dependence using combinations of ALIMTA (pemetrexed disodium, LY231514, MTA), gemcitabine and oxaliplatin in human colorectal carcinoma cell lines [abstract no. 503]. Clin Cancer Res 2000; 6: 4567S
12. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18: 1748-57
13. Tonkinson JL, Worzalla JF, Teng CH, et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59: 3671-6
14. Tesei A, Ricotti L, de Paola F, et al. In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and Gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 2002; 8: 233-9
15. Shargel L, Yu ABC. Dosage adjustment in renal disease. In: Shargel L, Yu ABC, editors. Applied biopharmaceutics and pharmacokinetics. 2nd ed. Norwalk (CT): Appleton-Century-Crofts, 1985: 305-330
16. Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 1987; 60: 1151-8
17. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1: 545-52
18. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 1992; 10: 239-53
19. Fleming TR. One-sample multiple testing procedure for phase 2 clinical trials. Biometrics 1982; 38: 143-51
20. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. JASA 1958; 53: 457-81
21. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine. Cancer 1999; 85: 1261-8
22. Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res 1998; 18: 3235-9
23. Vogelzang NJ, Rusthoven J, Symanowski JJ, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21 (14): 2636-44
24. Tempero M, Plunkett W, Ruizvan Haperen V, et al. Randomized phase II trial of dose intense gemcitabine by standard infusion vs fixed dose rate in metastatic pancreatic adenocarcinoma [abstract]. Proc Am Soc Clin Oncol 1999; 18: 237a
25. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma; Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-5